Nolet (Nebivolol)

Nebivolol, the active ingredient in Nolet, is a beta‑1 adrenergic receptor blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Nolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from batch‑to‑batch consistency, regulatory compliance, and responsive technical support. GNH USA also offers flexible packaging options to meet regional market requirements.

Nebivolol is indicated for conditions within the hypertension disease family, where it helps control elevated blood pressure. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Hypertension in the elderly: provides effective blood pressure control with a favorable tolerability profile in older adults. - Hypertension with cardiovascular risk: contributes to blood pressure reduction in patients who have additional risk factors such as dyslipidemia or coronary artery disease.

Nebivolol may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Nasal congestion - Peripheral edema - Nausea

Serious or Rare Side Effects: - Bradycardia - Severe hypotension - Heart block - Bronchospasm - Allergic reactions such as rash or angioedema

When prescribing nebivolol, clinicians should consider several precautionary measures to ensure patient safety. - Blood pressure monitoring: regularly assess blood pressure to confirm therapeutic response. - Cardiac function evaluation: review baseline heart rate and ECG, especially in patients with conduction disorders. - Asthma or COPD caution: use with care in patients with reactive airway disease due to potential bronchoconstriction. - Concomitant beta‑blocker use: avoid combining with other beta‑blockers unless clinically justified. - Renal impairment adjustment: consider dose modification in patients with severe renal dysfunction. - Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects may cause excessive bradycardia. - Calcium channel blockers verapamil or diltiazem: increased risk of AV‑block and heart failure. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise nebivolol plasma concentrations, enhancing adverse effects. - Non‑selective beta‑blockers: may lead to excessive β‑adrenergic blockade.

Moderate Interactions (Monitor Closely): - Diuretics: concurrent use may potentiate hypotensive response. - ACE inhibitors or ARBs: monitor for additive blood pressure lowering. - NSAIDs: may reduce antihypertensive effect of nebivolol. - Antiarrhythmic agents (e.g., amiodarone): observe for conduction abnormalities. - Antidiabetic drugs: monitor glucose control as blood pressure changes can affect glycemic levels.